221 related articles for article (PubMed ID: 19453993)
21. Performance of a hybrid central venous catheter utilized for both peripheral blood stem cell harvest and transplant support of patients undergoing autologous peripheral blood stem cell transplantation.
Restrepo A; Devore P; Encarnación CE; Wholey MH; Schneider D; Callander NS; Ferral H; Postoak D; Anderson JE; Walsh T; Padayao G; Gokmen E; Ehsan A; Ochoa L; Neumon B; West G; Restrepo MI; Przykucki J; Patterson J; Freytes CO
Bone Marrow Transplant; 2002 Sep; 30(6):389-95. PubMed ID: 12235524
[TBL] [Abstract][Full Text] [Related]
22. A predictive model of varicella-zoster virus infection after autologous peripheral blood progenitor cell transplantation.
Offidani M; Corvatta L; Olivieri A; Mele A; Brunori M; Montanari M; Rupoli S; Scalari P; Leoni P
Clin Infect Dis; 2001 May; 32(10):1414-22. PubMed ID: 11317241
[TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder presenting with skin involvement after CD34-selected autologous peripheral blood stem cell transplantation.
Takahashi S; Watanabe D; Miura K; Ozawa H; Tamada Y; Hara K; Matsumoto Y
Eur J Dermatol; 2007; 17(3):242-4. PubMed ID: 17478388
[TBL] [Abstract][Full Text] [Related]
24. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma.
Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297
[TBL] [Abstract][Full Text] [Related]
25. Human cytomegalovirus-specific T cell reconstitution in young patients receiving T cell-depleted, allogeneic hematopoietic stem cell transplantation.
Lilleri D; Gerna G; Fornara C; Chiesa A; Comolli G; Zecca M; Locatelli F
J Infect Dis; 2009 Mar; 199(6):829-36. PubMed ID: 19239337
[TBL] [Abstract][Full Text] [Related]
26. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2.
Nachbaur D; Kropshofer G; Feichtinger H; Allerberger F; Niederwieser D
Bone Marrow Transplant; 1997 Jun; 19(12):1261-3. PubMed ID: 9208124
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell transplantation in autoimmune diseases: the Ahmedabad experience.
Vanikar AV; Modi PR; Patel RD; Kanodia KV; Shah VR; Trivedi VB; Trivedi HL
Transplant Proc; 2007 Apr; 39(3):703-8. PubMed ID: 17445577
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases.
Auner HW; Zebisch A; Ofner P; Sill H; Linkesch W; Krause R
Ann Hematol; 2005 Aug; 84(8):532-7. PubMed ID: 15809882
[TBL] [Abstract][Full Text] [Related]
29. Unexpected immune complications in patients with non-Hodgkin's lymphoma receiving CD34-selected autologous peripheral stem cell transplantation.
Cordoba R; Arranz R; Cannata J
Bone Marrow Transplant; 2005 Jun; 35(12):1217-8. PubMed ID: 15852026
[No Abstract] [Full Text] [Related]
30. Severe sepsis in autologous stem cell transplant recipients: microbiological aetiology, risk factors and outcome.
Hamalainen S; Kuittinen T; Matinlauri I; Nousiainen T; Koivula I; Jantunen E
Scand J Infect Dis; 2009; 41(1):14-20. PubMed ID: 18836947
[TBL] [Abstract][Full Text] [Related]
31. Immune reconstitution, infectious complications and post transplant supportive care measures after autologous blood and marrow transplantation in children.
Machatschek J; Duda J; Matthay K; Cowan M; Horn B
Bone Marrow Transplant; 2003 Oct; 32(7):687-93. PubMed ID: 13130316
[TBL] [Abstract][Full Text] [Related]
32. Stem cell transplantation for severe autoimmune diseases: new proposals but still unanswered questions.
Marmont AM; Van Bekkum DW
Bone Marrow Transplant; 1995 Oct; 16(4):497-8. PubMed ID: 8528163
[TBL] [Abstract][Full Text] [Related]
33. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
[TBL] [Abstract][Full Text] [Related]
34. Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.
Labonté L; Li Y; Yang L; Gillingham A; Halpenny M; Giulivi A; Sills T; Evans K; Zanke B; Allan DS
Exp Hematol; 2009 Jun; 37(6):673-8. PubMed ID: 19463769
[TBL] [Abstract][Full Text] [Related]
35. Fatal ongoing human cytomegalovirus reactivation during high-dose melphalan and autologous stem cell transplantation.
Focosi D; Sordi E; Papineschi F; Benedetti E; Galimberti S; Petrini M
J Med Virol; 2009 May; 81(5):857-60. PubMed ID: 19319946
[TBL] [Abstract][Full Text] [Related]
36. Immunological reconstitution after autologous hematopoietic stem cell transplantation in patients with systemic sclerosis: relationship between clinical benefits and intensity of immunosuppression.
Bohgaki T; Atsumi T; Bohgaki M; Furusaki A; Kondo M; Sato-Matsumura KC; Abe R; Kataoka H; Horita T; Yasuda S; Amasaki Y; Nishio M; Sawada K; Shimizu H; Koike T
J Rheumatol; 2009 Jun; 36(6):1240-8. PubMed ID: 19447934
[TBL] [Abstract][Full Text] [Related]
37. Interferon gamma 13-CA-repeat homozygous genotype and a low proportion of CD4(+) lymphocytes are independent risk factors for cytomegalovirus reactivation with a high number of copies in hematopoietic stem cell transplantation recipients.
Jaskula E; Dlubek D; Duda D; Bogunia-Kubik K; Mlynarczewska A; Lange A
Biol Blood Marrow Transplant; 2009 Oct; 15(10):1296-305. PubMed ID: 19747638
[TBL] [Abstract][Full Text] [Related]
38. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation.
Castagnola E; Faraci M
Expert Rev Anti Infect Ther; 2009 Jun; 7(5):607-21. PubMed ID: 19485800
[TBL] [Abstract][Full Text] [Related]
39. Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation.
Barba P; Piñana JL; Valcárcel D; Querol L; Martino R; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1439-46. PubMed ID: 19822304
[TBL] [Abstract][Full Text] [Related]
40. Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Distler E; Schnürer E; Wagner E; von Auer C; Plachter B; Wehler D; Huber C; Kolbe K; Meyer RG; Herr W
Biol Blood Marrow Transplant; 2008 Dec; 14(12):1417-24. PubMed ID: 19041065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
